Product Description
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.
Biovision | 7167 | IGF-BP7 human recombinant DataSheet
Biomolecule/Target: IGF-BP7
Synonyms: Insulin-like growth factor binding protein-7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBPrP1)
Alternates names: Superoxide dismutase [Mn], mitochondrial, IPOB, MNSOD, MVCD6.
Taglines: Plays a role in skeletal myogenesis by binding to IGF
NCBI Gene ID #: 6648
NCBI Gene Symbol: SOD2
Gene Source: Human
Accession #: P04179
Recombinant: Yes
Source: E. Coli
Purity by SDS-PAGEs: 95%
Assay: SDS-PAGE
Purity: N/A
Assay #2: HPLC
Endotoxin Level: < 0.1 ng/g of protein (<1EU/g).
Activity (Specifications/test method): N/A
Biological activity: Specific activity is > 1,200 units/mg
Results: >1,200 units/mg
Binding Capacity: N/A
Unit Definition: N/A
Molecular Weight: 24.4 kDa (219 aa, 25-222 aa + His Tag)
Concentration: N/A
Appearance: Lyophilized powder
Physical form description: Sterile filtered through a 0.2 micron filter. Lyophilized from 10 mM Acetic Acid
Reconstitution Instructions: N/A
Amino acid sequence: MGSSHHHHHH SSGLVPRGSH MKHSLPDLPY DYGALEPHIN AQIMQLHHSK HHAAYVNNLN VTEEKYQEAL AKGDVTAQIA LQPALKFNGG GHINHSIFWT NLSPNGGGEP KGelLEAIKR DFGSFDKFKE KLTAASVGVQ GSGWGWLGFN KERGHLQIAA CPNQDPLQGT TGLIPLLGID VWEHAYYLQY KNVRPDYLKA IWNVINWENV TERYMACKK